Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan
| Autor: | Satoshi Takeuchi, Osamu Maehara, Akihiro Homma, Shunsuke Ohnishi, Naoya Sakamoto, Mitsuteru Natsuizaka, Akihisa Nakamura, Ren Yamada, Takashi Kitagataya, Megumi Kimura, Yoshito Komatsu, Koji Yamamoto, Kazunori Nagashima, Takehiko Katsurada, Goki Suda, Takashige Abe, Jun Sakakibara-Konishi, Masatsugu Ohara, Takanori Teshima, Machiko Umemura, Hiroo Hata, Masato Nakai, Kenichi Morikawa, Koji Ogawa, Naoki Kawagishi, Takuya Sho, Kazuharu Suzuki, Taku Shigesawa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty immune checkpoint inhibitor Ipilimumab Pembrolizumab Antibodies Monoclonal Humanized Severity of Illness Index Gastroenterology Antineoplastic Agents Immunological Japan irAE Internal medicine Prevalence medicine Humans hepatitis Risk factor Adverse effect Aged Retrospective Studies Aged 80 and over Hepatitis Hepatology business.industry Incidence (epidemiology) Retrospective cohort study Middle Aged medicine.disease adverse events immune system Nivolumab female risk factor Chemical and Drug Induced Liver Injury business Forecasting medicine.drug |
| Zdroj: | Journal of Gastroenterology and Hepatology. 35:1782-1788 |
| ISSN: | 1440-1746 0815-9319 |
| DOI: | 10.1111/jgh.15041 |
| Popis: | Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. Methods In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade >= 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade >= 3 after ICI initiation. The clinical course of grade >= 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade >= 3 irAE hepatitis. Conclusions Grade >= 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade >= 3 irAE hepatitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text